Posted on

GSK Receives FDA Approval of Arnuity Ellipta for Asthma in Children From 5 Years of Age

GSK Receives FDA Approval of Arnuity Ellipta for Asthma in Children From 5 Years of Age
London, UK 21 May 2018 --GSK today announced it has received approval from the US Food and Drug Administration (FDA) for the use of Arnuity Ellipta (fluticasone furoate) a once-daily inhaled corticosteroid (ICS) medicine for the maintenance ... .... ( read more )
Orginally Published At: New Drug Approvals